Monday Lunch livestream with Dr Ryan Cross
Developing Novel Chimeric Antigen Receptors for Brain Cancer
Join Dr Ryan Cross, postdoctoral researcher in the Jenkins Lab (WEHI), who will explain how the genetic enhancement of white blood cells (T-cells), are used to express a synthetic receptor called a Chimeric Antigen Receptor (CAR). This process can be employed to develop exciting new therapies for brain cancer including Glioblastoma.
Glioblastoma is the most aggressive form of brain cancer with an average life expectancy of just over a year following diagnosis. Unfortunately, there have been no new therapies since the introduction of the chemotherapy drug, Temozolomide, in 2005.